Roivant Sciences (ROIV) Stock Forecast & Price Target

Compare

698 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ROIV Analyst Ratings

Strong Buy

7 Buy

1 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Roivant

Sciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ROIV Stock 12 Month Forecast

Average Price Target

$27.25

▲(20.04% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Roivant Sciences in the last 3 months. The average price target is $27.25 with a high forecast of $33.00 and a low forecast of $22.00. The average price target represents a 20.04% change from the last price of $22.70.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","21":"$21","34":"$34","14.5":"$14.5","27.5":"$27.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$33.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$27.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,14.5,21,27.5,34],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.22,21.20307692307692,22.186153846153847,23.16923076923077,24.15230769230769,25.135384615384616,26.11846153846154,27.10153846153846,28.084615384615383,29.067692307692308,30.05076923076923,31.033846153846156,32.01692307692308,{"y":33,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.22,20.76076923076923,21.30153846153846,21.842307692307692,22.38307692307692,22.923846153846153,23.464615384615385,24.005384615384614,24.546153846153846,25.086923076923078,25.627692307692307,26.16846153846154,26.70923076923077,{"y":27.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.22,20.356923076923074,20.493846153846153,20.63076923076923,20.767692307692307,20.904615384615383,21.04153846153846,21.178461538461537,21.315384615384616,21.45230769230769,21.58923076923077,21.726153846153846,21.863076923076925,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.48,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.83,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.13,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.74,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.58,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.39,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.75,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.99,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.22,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$33.00

Average Price Target$27.25

Lowest Price Target$22.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yatin Suneja

Guggenheim

$25→$28

Buy

23.35%

Upside

Reiterated

12/18/25

Roivant Sciences price target raised to $28 from $25 at GuggenheimRoivant Sciences price target raised to $28 from $25 at Guggenheim

David Risinger

Leerink Partners

$22→$32

Buy

40.97%

Upside

Reiterated

12/15/25

Roivant Sciences: Promising Future with Strong Pipeline and Financial Stability

Corinne Johnson

Goldman Sachs

$24→$33

Buy

45.37%

Upside

Reiterated

12/15/25

Goldman Sachs Keeps Their Buy Rating on Roivant Sciences (ROIV)

Douglas Tsao

H.C. Wainwright

$26

Buy

14.54%

Upside

Reiterated

12/14/25

Roivant Sciences: Promising Outlook with Phase 3 Success and Robust Pipeline Drives Buy Rating

Brian Cheng

J.P. Morgan

$26

Buy

14.54%

Upside

Initiated

12/12/25

JPMorgan extends Roivant top pick status, adds to Analyst Focus ListJPMorgan extends Roivant top pick status, adds to Analyst Focus List

Samantha Semenkow

Citi

$25→$26

Buy

14.54%

Upside

Reiterated

11/11/25

Roivant Sciences price target raised to $26 from $25 at CitiRoivant Sciences price target raised to $26 from $25 at Citi

Yaron Werber

TD Cowen

$23→$28

Buy

23.35%

Upside

Reiterated

11/10/25

Promising Developments and Strong Financial Position Justify Buy Rating for Roivant Sciences

Chi Meng Fong

Bank of America Securities

$16.5→$22

Hold

-3.08%

Downside

Reiterated

11/10/25

Roivant Sciences (ROIV) Receives a Hold from Bank of America Securities

Prakhar Agrawal

Cantor Fitzgerald

Buy

―

Reiterated

06/18/25

Cantor Fitzgerald Sticks to Their Buy Rating for Roivant Sciences (ROIV)

Dennis Ding

Jefferies

$18

Buy

-20.70%

Downside

Reiterated

03/11/25

Strategic Growth Potential in Roivant Sciences: Capitalizing on Graves' Disease Market and FcRn Indications

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yatin Suneja

Guggenheim

$25→$28

Buy

23.35%

Upside

Reiterated

12/18/25

Roivant Sciences price target raised to $28 from $25 at GuggenheimRoivant Sciences price target raised to $28 from $25 at Guggenheim

David Risinger

Leerink Partners

$22→$32

Buy

40.97%

Upside

Reiterated

12/15/25

Roivant Sciences: Promising Future with Strong Pipeline and Financial Stability

Corinne Johnson

Goldman Sachs

$24→$33

Buy

45.37%

Upside

Reiterated

12/15/25

Goldman Sachs Keeps Their Buy Rating on Roivant Sciences (ROIV)

Douglas Tsao

H.C. Wainwright

$26

Buy

14.54%

Upside

Reiterated

12/14/25

Roivant Sciences: Promising Outlook with Phase 3 Success and Robust Pipeline Drives Buy Rating

Brian Cheng

J.P. Morgan

$26

Buy

14.54%

Upside

Initiated

12/12/25

JPMorgan extends Roivant top pick status, adds to Analyst Focus ListJPMorgan extends Roivant top pick status, adds to Analyst Focus List

Samantha Semenkow

Citi

$25→$26

Buy

14.54%

Upside

Reiterated

11/11/25

Roivant Sciences price target raised to $26 from $25 at CitiRoivant Sciences price target raised to $26 from $25 at Citi

Yaron Werber

TD Cowen

$23→$28

Buy

23.35%

Upside

Reiterated

11/10/25

Promising Developments and Strong Financial Position Justify Buy Rating for Roivant Sciences

Chi Meng Fong

Bank of America Securities

$16.5→$22

Hold

-3.08%

Downside

Reiterated

11/10/25

Roivant Sciences (ROIV) Receives a Hold from Bank of America Securities

Prakhar Agrawal

Cantor Fitzgerald

Buy

―

Reiterated

06/18/25

Cantor Fitzgerald Sticks to Their Buy Rating for Roivant Sciences (ROIV)

Dennis Ding

Jefferies

$18

Buy

-20.70%

Downside

Reiterated

03/11/25

Strategic Growth Potential in Roivant Sciences: Capitalizing on Graves' Disease Market and FcRn Indications

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Roivant Sciences

1 Month

xxx

Success Rate

12/16 ratings generated profit

Average Return

+7.33%

initiated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +7.33% per trade.

3 Months

xxx

Success Rate

13/16 ratings generated profit

Average Return

+21.71%

initiated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 81.25% of your transactions generating a profit, with an average return of +21.71% per trade.

1 Year

David RisingerLeerink Partners

Success Rate

32/35 ratings generated profit

Average Return

+58.58%

reiterated a buy rating 4 days ago

Copying David Risinger's trades and holding each position for 1 Year would result in 91.43% of your transactions generating a profit, with an average return of +58.58% per trade.

2 Years

xxx

Success Rate

17/17 ratings generated profit

Average Return

+86.16%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +86.16% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ROIV Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ROIV has received 11 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. ROIV average Analyst price target in the past 3 months is 27.25.

Each month's total comprises the sum of three months' worth of ratings.

ROIV Financial Forecast

ROIV Earnings Forecast

Next quarter’s earnings estimate for ROIV is -$0.31 with a range of -$0.45 to -$0.17. The previous quarter’s EPS was -$0.20. ROIV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ROIV has Performed in-line its overall industry.

ROIV Sales Forecast

Next quarter’s sales forecast for ROIV is $5.13M with a range of $0.00 to $15.00M. The previous quarter’s sales results were $1.57M. ROIV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ROIV has Performed in-line its overall industry.

ROIV Stock Forecast FAQ

What is ROIV’s average 12-month price target, according to analysts?

Based on analyst ratings, Roivant Sciences Ltd.’s 12-month average price target is 27.25.

What is ROIV’s upside potential, based on the analysts’ average price target?

Roivant Sciences Ltd. has 20.04% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ROIV a Buy, Sell or Hold?

Roivant Sciences Ltd. has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.

What is Roivant Sciences Ltd.’s price target?

The average price target for Roivant Sciences Ltd. is 27.25. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $33.00 ,the lowest forecast is $22.00. The average price target represents 20.04% Increase from the current price of $22.7.

What do analysts say about Roivant Sciences Ltd.?

Roivant Sciences Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of ROIV?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Roivant Sciences (ROIV) Stock Forecast & Price Target

ROIV Analyst Ratings

ROIV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Roivant Sciences

ROIV Analyst Recommendation Trends

ROIV Financial Forecast

ROIV Earnings Forecast

ROIV Sales Forecast

ROIV Stock Forecast FAQ

Detailed List of Analyst Forecasts